| Today’s Big NewsMar 22, 2024 |
| By Gabrielle Masson After GSK’s $2 billion buyout of Canada-based Bellus Health last summer, an undisclosed number of the biotech’s team members are out of a job. |
|
|
|
By Fraiser Kansteiner At a watershed moment for Duchenne muscular dystrophy treatment, privately held Italian drugmaker Italfarmaco has added a new therapeutic option to the armamentarium against the debilitating muscle-wasting disorder. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Conor Hale Researchers at the University of Washington's Baker Lab have shown that a generative AI program can help draw up atomically accurate antibodies from scratch—including those capable of binding to the proteins found in COVID-19, RSV and influenza. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now. 
|
|
By Angus Liu David Ricks’ visit to China comes as Lilly has several key drug applications under review at local regulators. |
By Nick Paul Taylor Nkarta’s CAR NK blood cancer candidate has again stalled after making a speedy start. The response rate fell away sharply in the latest update, mirroring what happened in an earlier cohort and driving the cell therapy developer to mothball the program. |
By Conor Hale Following two injuries and two deaths, the FDA is getting the word out on a recall of millions of hand-powered bag valve masks that may not deliver enough oxygen to a patient. |
By Kevin Dunleavy With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once-weekly basal insulin icodec) to the market. It was one of several opinions handed down by the CHMP. |
By Gabrielle Masson,Max Bayer,Andrea Park Bayer’s pharmaceutical reinvention is continuing with a pair of new title additions for two members of the leadership team. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
